Featured Research

from universities, journals, and other organizations

Penn Researchers To Study Treatment Options For "Eye Attacks"

Date:
January 12, 2001
Source:
University Of Pennsylvania Medical Center
Summary:
The terms “heart attack” and “brain attack” have become commonplace, but now neuro-ophthalmologists are waging war on the all too common, underreported, and untreated condition referred to as “eye attacks.” These attacks, known medically as Ischematic Optic Neuropathy (“ION”), result from a sudden lack of blood flow to the eye. Eye attacks, which are usually painless, can develop quite rapidly--sometimes overnight, often with catastrophic consequences to the vision of the individual, such as a sudden and permanent loss of peripheral or central vision in one eye.

The terms “heart attack” and “brain attack” have become commonplace, but now neuro-ophthalmologists are waging war on the all too common, underreported, and untreated condition referred to as “eye attacks.” These attacks, known medically as Ischematic Optic Neuropathy (“ION”), result from a sudden lack of blood flow to the eye. Eye attacks, which are usually painless, can develop quite rapidly--sometimes overnight, often with catastrophic consequences to the vision of the individual, such as a sudden and permanent loss of peripheral or central vision in one eye. The resulting visual impairment and the degree of severity usually varies from patient to patient but can include loss of the bottom half of one’s vision and difficulty with light and darkness.

Related Articles


University of Pennsylvania Medical Center researchers are working to help educate the public about this condition, which is the most common cause of acute optical nerve disease in adults over 50 years of age. While the frequency of the condition is estimated to occur in only a couple of people per thousand, per year, the catastrophic results are unquestioned. Studies indicate that irreversible damage can occur as quickly as within the first 90 seconds of the attack. “Prompt acknowledgement and treatment of the problem are essential if there is any chance of minimizing present and future damage”, says neuro-ophthalmologist and researcher Nicholas J. Volpe MD, Associate Professor of Ophthalmology & Neurology at the University of Pennsylvania’s Scheie Eye Institute. However, a new multi-center clinical trial, funded by the pharmaceutical company Allergan, is about to commence at approximately 50 research sites across the country, including the Scheie Eye Institute. The goal of the study is to determine whether neuro-protection-- i.e., delivering a proprietary and investigational topical agent to help a damaged nerve-- is viable. Specifically, Allergan is testing eye drops that will hopefully minimize collateral losses to the eye by saving some of the optic nerve fibers.

Contributing to the sense of urgency in promoting public awareness is the fact that most sufferers do not come forward and report the condition-- believing it, instead, to be a problem with their glasses or just a temporary, passing phase. This failure in reporting is critical, as researchers have been hampered by limited access to affected persons in a timely manner. Early reporting is essential as evidence now suggests that measures designed to limit further damage are most likely to succeed if intervention occurs within the first several hours. In addition, evidence exists that an attack in the other eye occurs up to 15 % of the time, over the following five years. Currently, a daily dose of aspirin is the only treatment offered, having a potential prophylactic effect on the second eye. Eye attacks, which are not a new occurrence, have been treated over the years by using steroids and surgical intervention--neither with much success. A visual problem that typically occurs later in life as part of the aging process, “ION” is also suspected to occur with increased frequency in patients with diabetes and hypertension, in addition to occurring frequently in people with small, crowded optic nerves. At this time, little can be done for the damaged eye, therefore successful prevention of second eye involvement is another goal of new research studies. A secondary and independent research study is also being performed by Volpe in conjunction with Carolyn Glazer, MD and Juan Grunwald MD, a retinal blood flow expert, also with Penn’s Scheie Eye Institute. This study will attempt to focus on the characteristics and nature of the blood flow patterns in a patient’s healthy eye, once he or she has suffered an eye attack. By examining the characteristics of the optic nerve in the healthy eye, the researchers hope to develop treatment strategies that can be used to protect the second eye.


Story Source:

The above story is based on materials provided by University Of Pennsylvania Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Pennsylvania Medical Center. "Penn Researchers To Study Treatment Options For "Eye Attacks"." ScienceDaily. ScienceDaily, 12 January 2001. <www.sciencedaily.com/releases/2001/01/010111073731.htm>.
University Of Pennsylvania Medical Center. (2001, January 12). Penn Researchers To Study Treatment Options For "Eye Attacks". ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2001/01/010111073731.htm
University Of Pennsylvania Medical Center. "Penn Researchers To Study Treatment Options For "Eye Attacks"." ScienceDaily. www.sciencedaily.com/releases/2001/01/010111073731.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins